Xtrna Bio
Netherlands
unknown
unknown
Stage
1
Investors
About
Develops gene transfer therapy using transfer ribonucleic acid (tRNA) supplementation to treat inherited neurological disorders affecting peripheral nerves, particularly Charcot-Marie-Tooth disease type 2D.
Explore Xtrna Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.